Merck is expanding its respiratory-health portfolio, the company announced in a press release.
The pharmaceutical giant with significant operations throughout Montco announced a $9.2 billion agreement to acquire Cidara Therapeutics. The deal centers on CD388, a long-acting antiviral designed to prevent influenza in adults who face higher risks of complications.
CD388 is currently in a Phase 3 clinical trial following strong Phase 2b results that earned the drug both Fast Track and Breakthrough Therapy designations from the FDA.
The therapy uses a drug-Fc conjugate approach that combines a neuraminidase inhibitor with an antibody fragment, offering potential protection against both influenza A and B. Merck leaders say the candidate could complement vaccines and antivirals while offering year-round coverage for vulnerable patients.
Cidara executives called the acquisition a pivotal moment for the company, noting that Merck’s global reach is essential to bringing CD388 to market. Merck said the deal expands its respiratory pipeline at a time when influenza continues to drive significant illness and hospitalizations, particularly among older adults and those with chronic conditions.
The acquisition is expected to close in early 2026, pending shareholder approval and regulatory review.
To learn more about Merck’s new acquisition and the antiviral drug, visit Merck.
